Home > News

News

Page 1 of 5  > >>

18 Jun, 2009
Innocoll Announces Provisional Findings from its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
Category: 2008
Posted by: innocoll_admin
 

ASHBURN, Va., June 18th /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced positive provisional findings from its three phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatment and prevention of infection in diabetic foot ulcers.

[More]
31 Mar, 2009
Innocoll, Inc. Files 510 (k) application for CollaRx Lidocaine Sponge
Category: 2008
Posted by: innocoll_admin

ASHBURN, Va., March 31, 2009 /PRNewswire/ — Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Pharmaceuticals, has filed a US 510k application for its CollaRx™ Lidocaine Sponge for the management of painful wounds.

[More]
19 Mar, 2009
Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
Category: 2008
Posted by: innocoll_admin
ASHBURN, Va., March 19, 2009 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the second of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections.
[More]